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Abstract
Background
We assessed the diagnostic accuracy of Determine TB-LAM (LF-LAM) to screen for tuber-
culosis among ambulatory adults established in HIV care in South Africa.
Methods
A systematic sample of adults attending for HIV care, regardless of symptomatology, were
enrolled in the XPHACTOR study, which tested a novel algorithm for prioritising investigation
with Xpert MTB/RIF. In this substudy, restricted to participants with enrolment CD4<200x106/
l, urine was stored at enrolment for later testing with LF-LAM. Sputum was sent for immediate
Xpert MTB/RIF if any of: current cough, fever3 weeks, body mass index (BMI)<18.5kg/m2,
CD4<100x106/l (or <200x106/l if pre-ART), weight loss10% or strong clinical suspicion
were present; otherwise, sputum was stored for Xpert testing at study completion. Partici-
pants were reviewedmonthly, with reinvestigation if indicated, to 3 months, when sputum and
blood were taken for mycobacterial culture. We defined tuberculosis as “confirmed” if Xpert,
line probe assay or culture forM. tuberculosiswithin six months of enrolment were positive,
and “clinical” if tuberculosis treatment started without microbiological confirmation.
Results
Amongst 424 participants, 61% were female and 57% were taking ART (median duration
22 months); median age, CD4 and BMI were 39 years, 111x106/l, and 23 kg/m2. 56/424
(13%) participants had tuberculosis (40 confirmed, 16 clinical). 24/424 (5.7%) vs. 8/424
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(1.9%) were LAM-positive using grade 1 vs. grade 2 cut-off. Using grade 1 cut-off, sensitivity
for confirmed TB (all clinical TB excluded) was 12.5% (95% CI 4.2%, 26.8%) and in
CD4<100x106/l vs. CD4100x106/l was 16.7% (95% CI 4.7%, 37.4%) vs. 6.3% (95% CI
0.2%, 30.2%). Specificity was >95% irrespective of diagnostic reference standard, CD4
stratum, or whether grade 1 or grade 2 cut-off was used.
Conclusion
Sensitivity of LF-LAM is too low to recommend as part of intensified case finding in ambula-
tory patients established in HIV care.
Introduction
The global HIV-associated tuberculosis (TB) epidemic remains a huge public health challenge,
with sub-Saharan Africa accounting for the vast majority of HIV-positive individuals diag-
nosed with and dying from TB. [1] Diagnosis of TB in people living with HIV (PLHIV) is com-
plicated by limitations of available diagnostics and the effect of immunosuppression on clinical
presentation of TB, e.g. reliance on sputum samples, the high proportion with smear-negative
or extrapulmonary disease, [2] and slow turnaround time for mycobacterial culture. The
World Health Organization recommends, as part of activities to address HIV-related TB, regu-
lar screening for active TB of all PLHIV followed by Xpert MTB/RIF (Cepheid, Sunnyvale, CA)
as the primary diagnostic test. [3] Xpert MTB/RIF has far greater sensitivity than smear and
provides results in under two hours, but like mycobacterial culture is expensive and laboratory-
based, which presents challenges for resource-limited settings. [3]
Testing for lipoarabinomannan (LAM), a cell wall lipopolysaccharide specific to mycobacte-
ria that is detectable in urine, is attractive as a screening tool for PLHIV, given a low-cost
point-of-care lateral-flow LAM assay (LF-LAM) (Determine TB-LAM; Alere, USA), potential
for rapid TB diagnosis, low biosafety risk, and ease of sample collection. Evaluations of
LF-LAM as a screening tool for TB have been undertaken in ambulatory patients in Ethiopia
and South Africa either prior to antiretroviral therapy (ART) initiation, [4, 5] or on receiving a
positive HIV diagnosis at HIV counselling and testing services (HCT). [6, 7] In these groups
LF-LAM sensitivity, compared to bacteriologically-confirmed TB, was inadequate as a stand-
alone test, though improved at lower CD4 cell counts. When evaluated amongst hospitalised
HIV-positive patients with TB symptoms in Uganda and South Africa sensitivity was much
greater, particularly amongst those with advanced immunosuppression, suggesting utility as a
rule-in test in this population. [8–10]
There are no published studies, to our knowledge, evaluating LF-LAM as a screening tool
for TB as part of intensified case finding for ambulatory patients established in HIV care
(rather than at their initial assessment). The aim of our study was to evaluate the diagnostic
accuracy of LF-LAM among adults with advanced immunosuppression (CD4<200x106/l)
established in HIV care. Our study contributed data to a systematic review of LF-LAM for the
diagnosis and screening of active TB in PLHIV, which informed the recently published World
Health Organization (WHO) policy guidance.[11]
Methods
This “LAM” study was part of XPHACTOR, a prospective cohort study evaluating a risk-based
algorithm to prioritise Xpert MTB/RIF testing amongst adults attending for routine HIV care
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in South Africa. Fig 1 depicts XPHACTOR study flow and how participants entered the LAM
substudy.
XPHACTOR study population and recruitment
We enrolled a systematic sample of adults (aged18 years) attending four clinics in Gauteng
province for HIV care, irrespective of presence of symptoms suggestive of TB. Patients taking
anti-tuberculosis treatment within the previous 3 months were excluded. Patients were
enrolled into “on ART” (currently taking ART) and “pre-ART” (in HIV care but not taking
ART) groups. At the time of the study, ART eligibility comprised CD4350x106/l or WHO
clinical stage3.
XPHACTOR procedures
Enrolment. At enrolment, research staff administered a standardised questionnaire incor-
porating the WHO TB screening tool (any of current cough, fever, night sweats or uninten-
tional weight loss), measured height and weight, and recorded most recent clinic CD4 cell
count. Further investigation was prioritised according to the XPHACTOR algorithm with an
immediate spot sputum sample sent for Xpert MTB/RIF for (i) all assigned “high priority” (any
of: current cough, fever 3 weeks, body mass index (BMI)<18.5 kg/m2, CD4<100x106/l,
measured weight loss10% in preceding 6 months, or other feature raising high clinical suspi-
cion of TB); (ii) those in the pre-ART group with CD4<200x106/l at enrolment because of a
priori high risk of active TB. For all other participants a spot sputum sample was frozen at
-80°C within 24 hours for testing with Xpert MTB/RIF at the end of the study.
Follow-up. Participants were reviewed monthly to three months, with repeat WHO symp-
tom screen and a spot sputum requested for Xpert MTB/RIF if “high priority” by the study
algorithm at that visit. Those in the “on ART” group who were asymptomatic at enrolment
were telephoned at 1 and 2 months to update locator information but were not asked about TB
symptoms. At the 3-month visit, sputum (induced if necessary) and blood were collected for
mycobacterial culture in liquid media (Bactec MGIT 960 or 9240 systems) from all study par-
ticipants. We allowed the 3-month visit to be undertaken more than three months post-enrol-
ment in order to maximise study follow up.
Participants who submitted an Xpert sample were reviewed and if Xpert-positive, TB treat-
ment was initiated; if negative, further investigation in accordance with national guidelines was
facilitated (chest radiograph, sputum culture and trial of antibiotics).
Clinic medical records were reviewed at the end of the study to ascertain any additional TB
diagnoses. We recorded deaths through reports from participant-nominated contacts, clinic
staff, and by accessing the Department of Home Affairs vital statistics database using partici-
pants’ South African identification (ID) numbers, which enabled us to track vital status several
months after final study visit for those with valid ID numbers.
LAM substudy procedures
All participants with CD4<200x106/l were eligible for this substudy. Eligible participants were
asked to provide a spot urine sample in a sterile container at enrolment, which was stored at
2–8°C prior to freezing at -80°C within 24 hours of collection. At the end of the study samples
were thawed to ambient temperature and tested with LF-LAM by two trained laboratory tech-
nologists in accordance with training provided by Alere representatives. The technologists did
not have access to other bacteriological results when performing LF-LAM tests. Each test was
graded once, using the pre-January 2014 manufacturer’s reference card comprising five grades
TB Screening with LAM in an HIV Clinic
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Fig 1. XPHACTOR study flow and entry point to the LAM substudy. 1 Samples tested with LF-LAM at the end of the study. 2
High priority (any of: current cough, fever 3 weeks, body mass index (BMI) <18.5 kg/m2, CD4 <100x106/l, measured weight loss
10% in preceding 6 months, or other feature raising high clinical suspicion of TB); medium priority (any of: fever < 3 weeks, night
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of colour intensity with the least intense band assigned grade 1, absence of a band graded nega-
tive, and absence of control band deemed a failed test. [12]
TB Case Definitions
“Confirmed” TB was defined as a positive result on i) Xpert MTB/RIF or ii) line probe assay
(LPA) performed on cultured isolate for identification and susceptibility or iii)M. tuberculosis
(Mtb) culture, from any sample taken within six months of enrolment. Individuals who started
TB treatment within six months of enrolment, in the absence of microbiological confirmation
(including those with treatment starts reported at verbal autopsy) and those smear-positive in
the absence of an associated positive culture or LPA result, were assigned “clinical” TB. This
was based on the assumption that an HIV-positive adult with a positive test result or starting
TB treatment within 6 months after enrolment likely had active TB at enrolment, supported by
data from Zimbabwe which estimated the mean duration of smear-positivity prior to TB diag-
nosis amongst HIV-positive adults to be 18–33 weeks. [13] Furthermore individuals diagnosed
with clinical TB based on findings at the 3-month visit would only have started treatment after
the 3-month visit.
“Not TB” was defined as fulfilling all of the following: absence of criteria for confirmed or
clinical TB; alive at least 3 months after enrolment; and1 MTB culture or Xpert result from
any sample within 6 months of enrolment. Participants who did not fulfil the case definitions
for TB or “not TB” were deemed “unclassifiable” and excluded from the main analysis.
Statistical methods
Data were analysed using Stata 14 (Stata Corporation, College Station, TX, USA).
We did not undertake a formal sample size calculation for the LAM substudy as the sample
size was all those eligible from the parent study. The target sample size for XPHACTOR was
based on estimating the sensitivity of the study algorithm, the main aim of the study, with rea-
sonable precision.
We calculated sensitivity, specificity and predictive values with 95% confidence intervals
(CI) for LF-LAM using cut-offs of grade1+ and2+ to define LAM-positive against a diag-
nostic reference standard of i) confirmed plus clinical TB, and ii) confirmed TB with clinical
TB excluded from numerator and denominator. We also calculated these parameters for grade
1+ cut-off for subgroups stratified by CD4<100x106/l and CD4100x106/l.
We undertook an exploratory assessment of mortality at six months in all participants who
provided a urine specimen, assuming all without record of demise were alive: i) six months
after enrolment if they had valid South African ID number, or ii) at latest study / clinic visit
date (hereafter last visit) if no valid South African ID. Person-time was calculated from the
date of study enrolment until: date of death if death recorded within six months of enrolment,
and for all others six months from enrolment if valid South African ID or date of last visit if no
valid South African ID. We constructed Kaplan-Meier curves of survival probability by LAM
positivity using LAM grade1+ to define positivity, and compared mortality using Cox
regression.
sweats, measured weight loss <10% in preceding 6 months); low priority = no TB symptoms. 3 Samples tested with Xpert MTB/RIF
at the end of the study. 4 High priority (any of: current cough, fever 3 weeks, night sweats 4 weeks, body mass index (BMI)
<18.5 kg/m2, CD4 <100x106/l, measured weight loss10% in preceding 6 months, or other feature raising high clinical suspicion of
TB).
doi:10.1371/journal.pone.0156866.g001
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Ethics statement
The study was approved by the ethics committees at the University of the Witwatersrand, Uni-
versity of Cape Town, and the London School of Hygiene & Tropical Medicine. All participants
gave written informed consent, or witnessed verbal consent if unable to write. For illiterate par-
ticipants, an impartial witness was present during the consenting process, and signed the wit-
ness section of the consent form. All ethics committees approved this consent procedure.
Consent and participation in the study was voluntary. Participants were able to refuse to take
part, with no consequences to their healthcare or any other services as a result of refusal.
Results
Between September 2012 and March 2014 we enrolled 3508 participants established in HIV
care, of whom 586 had CD4<200x106/l and were eligible for the LAM substudy. 80% (469/
586) provided a urine sample, and the remaining 20% (117/586) did not, as unable (93) or rea-
son not recorded (24) (Fig 2); 67% (395/586) provided a spot sputum sample at enrolment. 44
participants were excluded because unclassifiable: no TB diagnosed but absence of any TB
microbiology results (26); death within three months of enrolment (14); and TB diagnosed>6
months after enrolment (4); and one sample could not be tested as damaged, leaving 424 eligi-
ble for evaluation of diagnostic accuracy of LF-LAM.
There was little difference in WHO-tool positivity or gender amongst those providing
(N = 469) vs. not providing urine (N = 117): 52% vs. 44%WHO-tool positive (p = 0.1) and
61% vs. 62% female (p = 0.7). Median CD4 was lower in those providing urine compared with
Fig 2. Flow chart of study participants. LAM+ defined as grade 1.
doi:10.1371/journal.pone.0156866.g002
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those who did not (110 vs. 140x106/l [p = 0.01]); and a greater proportion also provided spu-
tum at enrolment (74% vs. 42% [p<0.001]).
Participant characteristics
Characteristics of the 424 LAM substudy participants are presented in Table 1. The majority of
participants were female (61%), WHO-tool positive at enrolment (53%), and in the “on ART”
group (57%) amongst whom median duration of ART was 22 months (interquartile range
[IQR] 6, 52). Median age, CD4 and BMI at enrolment were respectively 39 years, 111x106/l,
and 23 kg/m2; and 30% had previously been treated for TB. In the “pre-ART” group, for 97%
(176/182) participants with reported date of first positive HIV test recorded, median duration
since HIV diagnosis was 20 days (IQR 10, 65). 94% (171/182) of “pre-ART” initiated ART
within median 9 days (IQR 4, 24) from enrolment (initiation date available for 170/171).
The proportion reporting each WHO-tool symptom was cough, 32% (134/424) with
median duration 14 days (interquartile range [IQR] 7,38); unintentional weight loss, 31% (131/
Table 1. Baseline characteristics of study participants.
All participants N = 424
Age-years
Median (IQR) 39 (32, 45)
Sex
Female 258 (60.8%)
Ethnic group
Black/African 421 (99.3%)
Participant category
Pre-ART 182 (42.9%)
On ART 242 (57.1%)
ART duration for those on ART, months median (IQR) 22 (6, 52)
Previous TB treatment
Yes 125 (29.5%)
Ever had IPT
Yes 18 (4.2%)
Ever had CPT
Yes 276 (65.1%)
Current diuretic use
Yes 10 (2.4%)
Enrolment WHO symptom screen
Positive 224 (52.8%)
Enrolment BMI-kg/m2 (N = 423)
Median (IQR) 23 (20, 27)
Enrolment CD4 x106/l 1
Median (IQR) 111 (56, 161)
Numbers are median (Interquartile range [IQR]) or number (%)
ART = Antiretroviral therapy; CPT = Co-trimoxazole preventive therapy; IPT = Isoniazid preventive therapy;
BMI = body mass index
WHO symptom screen positive = self-report of any of current cough, fever, night sweats or unintentional
weight loss
1 All participants had CD4<200x106/l
doi:10.1371/journal.pone.0156866.t001
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424); night sweats, 15% (65/424); fever, 10% (44/424); and 24% (102/424) reported more than
one symptom.
Tuberculosis diagnoses
13% (56/424) of participants fulfilled our case definitions for tuberculosis (7% [16/242] “on
ART” and 22% [40/182] “pre-ART”), amongst whom treatment start date was available for 53/
56, and was started at a median of 13 (IQR 5, 95) days from enrolment. 40/56 had confirmed
TB (25 Xpert-positive, 7 Mtb culture-positive, 7 both Xpert and Mtb culture-positive, 1 pleural
fluid cultured isolate LPA-positive) of whom 36/40 had pulmonary TB, 3/40 both pulmonary
and extrapulmonary TB, and 1/40 extrapulmonary TB only. 16/56 had clinical TB for whom
diagnosis was based on compatible chest radiograph or abdominal ultrasound (8), persistent
cough and weight loss (1), positive sputum smear (1), and unknown (6) including TB treat-
ment reported at verbal autopsy (2). Amongst those with clinical TB the site was pulmonary
(10/16), extrapulmonary (4/16), and not recorded (2/16).
Performance of urine LAM
LAM results were available for 424 participants. A positive LF-LAM result using grade 1 vs.
grade 2 cut-off was observed in 5.7% (24) vs. 1.9% (8) of participants. The distribution of
results was negative, 94% (400); grade 1, 3.8% (16); grade 2, 1.2% (5); grade 3, 0.5% (2); and
grade 5, 0.2% (1).
Table 2 summarises the performance of LF-LAM in our study population. Sensitivity for all
TB (clinical and confirmed) using grade 1 cut-off was 14.3% (95% CI 6.4%, 26.2%), similar if
reference standard was confirmed TB with all clinical TB excluded (12.5% [95% CI 4.2%,
26.8%]), but lower if grade 2 cut-off utilised (5.4% [95% CI 1.1%, 14.9%] for all TB). Sensitivity
was greater in participants with enrolment CD4<100 vs. CD4100x106/l: using grade 1 cut-
off 17.1% (95% CI 6.6%, 33.6%) vs. 9.5% (95% CI 1.2%, 30.4%) for all TB, and 16.7% (95% CI
4.7%, 37.4%) vs. 6.3% (95% CI 0.2%, 30.2%) for confirmed TB. Specificity of the test was>95%
irrespective of reference standard, CD4 stratum, or whether positivity was defined using grade
1 or grade 2 cut-off.
In a sensitivity analysis we included the 40 participants whom we deemed to have unclassifi-
able TB outcome, and considered those excluded because deceased within 3 months of enrol-
ment to have TB (N = 14), and those excluded because of absence of microbiology to not have
TB (N = 26). Against a reference standard for all TB (clinical and confirmed) and using grade 1
cut-off, the sensitivity and specificity of LF-LAM was 15.7% (95% CI 8.1, 26.4) and 95.7% (95%
CI 93.2, 97.5) respectively. If a grade 2 cut-off was used the sensitivity and specificity of
LF-LAM was 8.6% (95% CI 3.2, 17.7) and 98.7% (95% CI 97.1, 99.6) respectively.
There were five false positive LF-LAM rests using the grade 2 cut-off, of these one partici-
pant with CD4 of 4x106/l at enrolment hadM. avium isolated from sputum culture but was not
treated and was alive at six months. All of the remaining four participants with false positive
LF-LAM had negative sputum mycobacteriology during follow up and were alive at six
months.
Mortality
Amongst 468 participants with evaluable urine samples, 6% (28/468) were LF-LAM positive
using grade 1 cut-off, of whom 14% (4/28) died within six months of enrolment. Among the
440 who were LF-LAM negative, 5% (20/440) died (hazard ratio 3.6 [95%CI 1.2, 10.5],
p = 0.04; Fig 3).
TB Screening with LAM in an HIV Clinic
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Table 2. Diagnostic accuracy of LF-LAM among HIV clinic attendees with CD4<200.
Prevalence
of TB
Prevalence
of positive
LAM
Sensitivity Speciﬁcity PPV NPV
Gold standard = conﬁrmed* and clinical† TB n/N % n/N % n/
N
% (95% CI) n/N % (95% CI) n/
N
% (95% CI) n/N % (95% CI)
Grade 1‡ cut-off 56/
424
13.2% 24/
424
5.7% 8/
56
14.3% (6.4,
26.2)
352/
368
95.7%
(93.0, 97.5)
8/
24
33.3%
(15.6, 55.3)
352/
400
88.0%
(84.4, 91.0)
CD4 <100 35/
187
18.7% 12/
187
6.4% 6/
35
17.1% (6.6,
33.6)
146/
152
96.1%
(91.6, 98.5)
6/
12
50.0%
(21.1, 78.9)
146/
175
83.4%
(77.1, 88.6)
CD4 100 21/
237
8.9% 12/
237
5.1% 2/
21
9.5% (1.2,
30.4)
206/
216
95.4%
(91.7, 97.8)
2/
12
16.7% (2.1,
48.4)
206/
225
91.6%
(87.1, 94.8)
Grade 2§ cut-off 56/
424
13.2% 8/
424
1.9% 3/
56
5.4% (1.1,
14.9)
363/
368
98.6%
(96.9, 99.6)
3/8 37.5% (8.5,
75.5)
363/
416
87.3%
(83.7, 90.3)
Gold standard = conﬁrmed* TB (all clinical†
TB excluded) (N = 408)
Grade 1‡ cut-off 40/
408
9.8% 21/
408
5.1% 5/
40
12.5% (4.2,
26.8)
352/
368
95.7%
(93.0, 97.5)
5/
21
23.8% (8.2,
47.2)
352/
387
91.0%
(87.6, 93.6)
CD4 <100 24/
176
13.6% 10/
176
5.7% 4/
24
16.7% (4.7,
37.4)
146/
152
96.1%
(91.6, 98.5)
4/
10
40.0%
(12.2, 73.8)
146/
166
88.0%
(82.0, 92.5)
CD4 100 16/
232
6.9% 11/
232
4.7% 1/
16
6.3% (0.2,
30.2)
206/
216
95.4%
(91.7, 97.8)
1/
11
9.1% (0.2,
41.3)
206/
221
93.2%
(89.1, 96.2)
Grade 2§ cut-off 40/
408
9.8% 8/
408
2.0% 3/
40
7.5% (1.6,
20.4)
363/
368
98.6%
(96.9, 99.6)
3/8 37.5% (8.5,
75.5)
363/
400
90.8%
(87.5, 93.4)
* Conﬁrmed TB = positive on Xpert MTB/RIF or line probe assay or M. tuberculosis culture, from any sample taken within 6 months of enrolment
† Clinical TB = started TB treatment within 6 months of enrolment, in the absence of microbiological conﬁrmation and those smear-positive in the absence
of an associated culture
‡ Grade 1 positive: > = 1+
§ Grade 2 positive: > = 2+
NPV = Negative predictive value; PPV = Positive predictive value; CI = conﬁdence interval
doi:10.1371/journal.pone.0156866.t002
Fig 3. Kaplan-Meier curve comparing mortality between LAM positive (dashed line) and LAM negative
(solid line) participants using grade 1 cut-off. Y-axis range for cumulative mortality is 0 to 0.2
doi:10.1371/journal.pone.0156866.g003
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Discussion
We found very low sensitivity of LF-LAM for TB (whether confirmed, or also including clinical
diagnoses) among ambulatory outpatients established in HIV care with CD4<200x106/l,
which does not support its use for TB screening in this study population. Recent WHO
LF-LAM policy guidance recommends against use for TB screening, based on the systematic
review to which our data contributed, which reported (using grade 2 cut-off and microbiolog-
ical reference standard) a pooled sensitivity of only 23% for screening HIV-positive outpa-
tients.[11] Our study is the first reporting performance of LF-LAM among outpatients
established in HIV care. It adds to the published evaluations of LF-LAM amongst HIV-positive
adult outpatients screened for TB, which to date have only been undertaken in those newly
diagnosed [6, 7] or about to initiate ART, [4, 5] populations likely to be sicker than those
already in HIV care.
In our study, LF-LAM had a sensitivity of 13% using the grade1 cut-off (against con-
firmed TB as a gold standard) vs. reported 26–29% [4, 5] in those about to initiate ART, and
28–41% [6, 7] amongst those with a new HIV diagnosis. In those evaluations, sensitivity
improved greatly at lower CD4 counts, e.g. for confirmed TB from around 20% if
CD4100x106/l to>50% if CD4<100x106/l; our improvement from 10% to 17% is in accord
although still not useful for screening. [4–7] The sensitivity of LF-LAM is greater in those who
are sicker, and this test is most useful as a rapid rule-in tool for TB when used for HIV-positive
inpatients with symptoms suggestive of TB and advanced immunosuppression, a population
with high mortality; and its use in this setting is supported by the recent WHO guidance.[11]
In these populations sensitivity of 59–66% [9, 10] for culture-confirmed TB has been reported
from evaluations in South Africa and Uganda, increasing to 85% [10] when combined with
sputum Xpert MTB/RIF, thus potentially enabling rapid initiation of TB treatment. In contrast
our participants were established in HIV care, and we were evaluating the usefulness of
LF-LAM as part of a routine screening algorithm for intensified TB case finding in HIV clinic
attendees, although restricted to those with CD4 counts below 200x106/l for whom LF-LAM
was most likely to be useful. The median CD4 in our study population was 111x106/l which is
lower than the 170–248x106/l reported in outpatient evaluations, [4–7] and our participants
were frequently symptomatic, but in spite of this we found poor sensitivity for TB, possibly as
patients were less ill.
An obvious advantage of a urine-based diagnostic test is ease of specimen collection,
although privacy is clearly required. However, we found 20% of eligible patients did not pro-
vide a urine sample which, although less than the 33% unable to produce sputum spontane-
ously at enrolment, is still greater than 1–3% unable to produce urine in other outpatient
studies. [5, 7] We found no indication that those unable to produce urine were more unwell
than those who could, so this is unlikely to have affected our findings, although we acknowl-
edge this as a limitation of our study. Our study procedures were fitted around routine appoint-
ments in busy public sector clinics, and we postulate that time limitations may have
contributed, as these patients were also less likely to provide sputum at enrolment.
We found increased mortality amongst patients who were LF-LAM positive, consistent with
studies of sicker inpatient HIV-positive populations reporting LAM-positivity as a predictor
for mortality. [14, 15]
Strengths of our study include our systematic sampling and longitudinal follow-up, which
minimised the number of TB diagnoses missed. All samples for mycobacteriology collected
during the course of our study, many of which were sputum samples collected at enrolment,
contributed to our reference standard of “confirmed” TB. We undertook all LF-LAM tests at
study completion using frozen samples, but this is consistent with other published studies, and
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all our samples were stored in accordance with manufacturer’s recommendation with only one
freeze-thaw cycle, and processed within one year from collection. [16] A limitation of our
study is the exclusion of participants (N = 40) who were not diagnosed with TB but either did
not have any TB microbiology results or died within three months of enrolment, but our sensi-
tivity analysis shows that this made little difference to the performance of LF-LAM.
Conclusion
Despite the appeal of LF-LAM as a cheap, non-sputum based, point-of-care TB screening tool,
the low sensitivity in this population with advanced immunosuppression, of whom 13% had
TB, precludes recommendation for its use to screen for TB in ambulatory patients established
in HIV care in accordance with the recent WHO LF-LAM policy guidance.[11]
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